IMRX Quote, Financials, Valuation and Earnings

Fortress Biotech, Inc. has a net margin of -- compared to Immuneering Corp.'s net margin of 50.07%. Immuneering Corp.'s return on equity of -78.54% beat Fortress Biotech, Inc.'s return on equity of -223.06%.

Immuneering Corp. has a consensus price target of $16.83, signalling upside risk potential of 263.57%. On the other hand Fortress Biotech, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 246.77%. Given that Immuneering Corp. has higher upside potential than Fortress Biotech, Inc., analysts believe Immuneering Corp. is more attractive than Fortress Biotech, Inc..

Immuneering Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortress Biotech, Inc. has a beta of 1.423, suggesting its more volatile than the S&P 500 by 42.327%.

Immuneering Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuneering Corp. pays -- of its earnings as a dividend. Fortress Biotech, Inc. pays out 3.9% of its earnings as a dividend. Fortress Biotech, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Immuneering Corp. quarterly revenues are --, which are smaller than Fortress Biotech, Inc. quarterly revenues of $17.6M. Immuneering Corp.'s net income of -$15M is lower than Fortress Biotech, Inc.'s net income of $8.8M. Notably, Immuneering Corp.'s price-to-earnings ratio is -- while Fortress Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering Corp. is 323.21x versus 1.46x for Fortress Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Phathom Pharmaceuticals, Inc. has a net margin of -- compared to Immuneering Corp.'s net margin of -60.55%. Immuneering Corp.'s return on equity of -78.54% beat Phathom Pharmaceuticals, Inc.'s return on equity of --.

Immuneering Corp. has a consensus price target of $16.83, signalling upside risk potential of 263.57%. On the other hand Phathom Pharmaceuticals, Inc. has an analysts' consensus of $22.90 which suggests that it could grow by 67.52%. Given that Immuneering Corp. has higher upside potential than Phathom Pharmaceuticals, Inc., analysts believe Immuneering Corp. is more attractive than Phathom Pharmaceuticals, Inc..

Immuneering Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Phathom Pharmaceuticals, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.57%.

Immuneering Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phathom Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuneering Corp. pays -- of its earnings as a dividend. Phathom Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Immuneering Corp. quarterly revenues are --, which are smaller than Phathom Pharmaceuticals, Inc. quarterly revenues of $49.5M. Immuneering Corp.'s net income of -$15M is higher than Phathom Pharmaceuticals, Inc.'s net income of -$30M. Notably, Immuneering Corp.'s price-to-earnings ratio is -- while Phathom Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering Corp. is 323.21x versus 6.71x for Phathom Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of -- compared to Immuneering Corp.'s net margin of -40.15%. Immuneering Corp.'s return on equity of -78.54% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.

Immuneering Corp. has a consensus price target of $16.83, signalling upside risk potential of 263.57%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $13.63 which suggests that it could grow by 80.7%. Given that Immuneering Corp. has higher upside potential than Vanda Pharmaceuticals, Inc., analysts believe Immuneering Corp. is more attractive than Vanda Pharmaceuticals, Inc..

Immuneering Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.647%.

Immuneering Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuneering Corp. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Immuneering Corp. quarterly revenues are --, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Immuneering Corp.'s net income of -$15M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Immuneering Corp.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering Corp. is 323.21x versus 2.09x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Verastem, Inc. has a net margin of -- compared to Immuneering Corp.'s net margin of -876.34%. Immuneering Corp.'s return on equity of -78.54% beat Verastem, Inc.'s return on equity of -1773.4%.

Immuneering Corp. has a consensus price target of $16.83, signalling upside risk potential of 263.57%. On the other hand Verastem, Inc. has an analysts' consensus of $16.13 which suggests that it could grow by 164.34%. Given that Immuneering Corp. has higher upside potential than Verastem, Inc., analysts believe Immuneering Corp. is more attractive than Verastem, Inc..

Immuneering Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.438, suggesting its less volatile than the S&P 500 by 56.157%.

Immuneering Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuneering Corp. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.

Immuneering Corp. quarterly revenues are --, which are smaller than Verastem, Inc. quarterly revenues of $11.2M. Immuneering Corp.'s net income of -$15M is higher than Verastem, Inc.'s net income of -$98.5M. Notably, Immuneering Corp.'s price-to-earnings ratio is -- while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering Corp. is 323.21x versus 28.50x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.